The collection and use of real world data: Results from a 2009 survey of British Pharmaceutical companies
pH Associates have been working in collaboration with the Office of Health Economics (OHE) to conduct a survey of British Pharmaceutical companies to assess collection and use of real world data. The aims of this survey were to:
- Describe what industry is currently doing with respect to real-world evidence-gathering and evidence-generation for HTA submissions.
- Describe the perceived barriers, and to identify any relative advantages, of undertaking real-world studies in the UK, rather than in other countries.
- Seek views on the impact of real-world evidence on HTA processes, from an industry perspective.
- Provide an industry-wide perspective regarding the collection of data on health-related quality of life, effectiveness and cost of new medicines in real-world conditions.
The results showed that:
- The vast majority of British pharmaceutical companies are actively involved in generating or using real world data to inform HTA of their products.
- There are both perceived advantages and disadvantages of choosing the UK as the site for studies to collect real-world evidence.
- Views on whether real world data had a positive effect on NICE decisions was somewhat equivocal: most felt that where such data had been submitted, they were only somewhat important.
- Participants felt strongly that real world data were more likely to be important in providing evidence on outcomes in chronic conditions, cancer, and orphan areas.
The results were presented as a poster at the 13th ISPOR conference in Prague from 7 – 9th November 2010.
Please click here for a copy of the poster